Cargando…

Mendelian randomization for studying the effects of perturbing drug targets

Drugs whose targets have genetic evidence to support efficacy and safety are more likely to be approved after clinical development. In this paper, we provide an overview of how natural sequence variation in the genes that encode drug targets can be used in Mendelian randomization analyses to offer i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gill, Dipender, Georgakis, Marios K., Walker, Venexia M., Schmidt, A. Floriaan, Gkatzionis, Apostolos, Freitag, Daniel F., Finan, Chris, Hingorani, Aroon D., Howson, Joanna M.M., Burgess, Stephen, Swerdlow, Daniel I., Davey Smith, George, Holmes, Michael V., Dichgans, Martin, Scott, Robert A, Zheng, Jie, Psaty, Bruce M., Davies, Neil M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000 Research Limited 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903200/ https://www.ncbi.nlm.nih.gov/pubmed/33644404 http://dx.doi.org/10.12688/wellcomeopenres.16544.2

Ejemplares similares

Genetically Predicted Midlife Blood Pressure and Coronary Artery Disease Risk: Mendelian Randomization Analysis
por: Gill, Dipender, et al.
Publicado: (2020)

Interleukin-6 Signaling Effects on Ischemic Stroke and Other Cardiovascular Outcomes: A Mendelian Randomization Study
por: Georgakis, Marios K., et al.
Publicado: (2020)

Lipid lowering and Alzheimer disease risk: A mendelian randomization study
por: Williams, Dylan M., et al.
Publicado: (2019)

Additive Effects of Genetic Interleukin‐6 Signaling Downregulation and Low‐Density Lipoprotein Cholesterol Lowering on Cardiovascular Disease: A 2×2 Factorial Mendelian Randomization Analysis
por: Georgakis, Marios K., et al.
Publicado: (2021)

Associations of genetically predicted IL-6 signaling with cardiovascular disease risk across population subgroups
por: Georgakis, Marios K., et al.
Publicado: (2022)

Contextualizing selection bias in Mendelian randomization: how bad is it likely to be?
por: Gkatzionis, Apostolos, et al.
Publicado: (2019)

Dose–response relationship between genetically proxied average blood glucose levels and incident coronary heart disease in individuals without diabetes mellitus
por: Burgess, Stephen, et al.
Publicado: (2021)

Genetically Determined Platelet Count and Risk of Cardiovascular Disease: Mendelian Randomization Study
por: Gill, Dipender, et al.
Publicado: (2018)

Modifiable Lifestyle Factors and Risk of Stroke: A Mendelian Randomization Analysis
por: Harshfield, Eric L., et al.
Publicado: (2021)

Genetic drug target validation using Mendelian randomisation
por: Schmidt, Amand F., et al.
Publicado: (2020)

Statistical methods for cis‐Mendelian randomization with two‐sample summary‐level data
por: Gkatzionis, Apostolos, et al.
Publicado: (2022)

Circulating biomarkers of immunity and inflammation, risk of Alzheimer’s disease, and hippocampal volume: a Mendelian randomization study
por: Fani, Lana, et al.
Publicado: (2021)

Strategies to investigate and mitigate collider bias in genetic and Mendelian randomisation studies of disease progression
por: Mitchell, Ruth E., et al.
Publicado: (2023)

Relationship Between Blood Pressure and Incident Cardiovascular Disease: Linear and Nonlinear Mendelian Randomization Analyses
por: Malik, Rainer, et al.
Publicado: (2021)

Bayesian variable selection with a pleiotropic loss function in Mendelian randomization
por: Gkatzionis, Apostolos, et al.
Publicado: (2021)

Cardiometabolic Traits, Sepsis, and Severe COVID-19: A Mendelian Randomization Investigation
por: Ponsford, Mark J., et al.
Publicado: (2020)

Genetically Proxied Inhibition of Coagulation Factors and Risk of Cardiovascular Disease: A Mendelian Randomization Study
por: Yuan, Shuai, et al.
Publicado: (2021)

Cardiac Risk Factors for Stroke: A Comprehensive Mendelian Randomization Study
por: Frerich, Simon, et al.
Publicado: (2021)

Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome
por: Storm, Catherine S., et al.
Publicado: (2021)

Genetically Predicted Blood Pressure Across the Lifespan: Differential Effects of Mean and Pulse Pressure on Stroke Risk
por: Georgakis, Marios K., et al.
Publicado: (2020)

Genetic evidence for serum amyloid P component as a drug target for treatment of neurodegenerative disorders
por: Schmidt, A Floriaan, et al.
Publicado: (2023)

Genetically Predicted Blood Pressure and Risk of Atrial Fibrillation
por: Hyman, Matthew C., et al.
Publicado: (2021)

Diabetes Mellitus, Glycemic Traits, and Cerebrovascular Disease: A Mendelian Randomization Study
por: Georgakis, Marios K., et al.
Publicado: (2021)

Modal-based estimation via heterogeneity-penalized weighting: model averaging for consistent and efficient estimation in Mendelian randomization when a plurality of candidate instruments are valid
por: Burgess, Stephen, et al.
Publicado: (2018)

Genetic Determinants of Lipids and Cardiovascular Disease Outcomes: A Wide-Angled Mendelian Randomization Investigation
por: Allara, Elias, et al.
Publicado: (2019)

Selecting instruments for Mendelian randomization in the wake of genome-wide association studies
por: Swerdlow, Daniel I, et al.
Publicado: (2016)

The evolution of mendelian randomization for investigating drug effects
por: Gill, Dipender, et al.
Publicado: (2022)

The impact of fatty acids biosynthesis on the risk of cardiovascular diseases in Europeans and East Asians: a Mendelian randomization study
por: Borges, Maria-Carolina, et al.
Publicado: (2022)

Exploring the Role of Plasma Lipids and Statin Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study
por: Almramhi, Mona M., et al.
Publicado: (2023)

Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities
por: Walker, Venexia M, et al.
Publicado: (2017)

Anti-Epileptic Drug Target Perturbation and Intracranial Aneurysm Risk: Mendelian Randomization and Colocalization Study
por: Bakker, Mark K., et al.
Publicado: (2022)

Mendelian randomization applied to pharmaceutical use: the case of metformin and lung cancer
por: Yarmolinsky, James, et al.
Publicado: (2020)

Genetically determined blood pressure, antihypertensive drug classes, and risk of stroke subtypes
por: Georgakis, Marios K., et al.
Publicado: (2020)

Association of Smoking, Alcohol Consumption, Blood Pressure, Body Mass Index, and Glycemic Risk Factors With Age-Related Macular Degeneration: A Mendelian Randomization Study
por: Kuan, Valerie, et al.
Publicado: (2021)

Guidelines for performing Mendelian randomization investigations: update for summer 2023
por: Burgess, Stephen, et al.
Publicado: (2023)

Systemic iron status and maternal pregnancy complications: A Mendelian randomization study
por: Rogne, Tormod, et al.
Publicado: (2022)

Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization
por: Henry, Albert, et al.
Publicado: (2022)

Genetically Predicted Pulse Pressure and Risk of Abdominal Aortic Aneurysm: A Mendelian Randomization Analysis
por: Burgess, Stephen, et al.
Publicado: (2022)

Performance of polygenic risk scores in screening, prediction, and risk stratification: secondary analysis of data in the Polygenic Score Catalog
por: Hingorani, Aroon D, et al.
Publicado: (2023)

Smoking and heart failure: a Mendelian randomization and mediation analysis
por: Lu, Yunlong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bd2e3v5258sufqnvacvq7s4pon